Effects of pioglitazone in familial combined hyperlipidaemia

Journal of Internal Medicine

Volumn 259, Issue 1, 2006, Pages 107-116

  Abbink, E J ^a   De Graaf, J ^a   De Haan, J H ^a   Heerschap, A ^a   Stalenhoef, A F ^a   Tack, C J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Body fat distribution; Endothelial function; Familial combined hyperlipidaemia; Insulin sensitivity; Pioglitazone

Indexed keywords

ALKALINE PHOSPHATASE; GLYCERYL TRINITRATE; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN; NEUTRAL INSULIN; PIOGLITAZONE; PLACEBO; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ALANINE AMINOTRANSFERASE; ANTIDIABETIC AGENT; CHOLESTEROL;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; APPARATUS; ARTICLE; BLOOD FLOW; BODY FAT DISTRIBUTION; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; ENDOTHELIUM CELL; FAMILIAL HYPERLIPEMIA; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMAN; HYPERINSULINEMIC EUGLYCEMIC CLAMP; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; M MODE ECHOCARDIOGRAPHY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASODILATATION; BLOOD; MIDDLE AGED; PHYSIOLOGY; TREATMENT OUTCOME;

ALANINE TRANSAMINASE; CHOLESTEROL; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIPIDS; MALE; MIDDLE AGED; THIAZOLIDINEDIONES; TREATMENT OUTCOME; VASODILATION;

EID: 33644823712     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2005.01579.x     Document Type: Article

References (47)

1. Bredie SJ Demacker PN Stalenhoef AF Metabolic and genetic aspects of familial combined hyperlipidaemia with emphasis on low-density lipoprotein heterogeneity Eur J Clin Invest 1997 27 802 11
2. De Graaf J Stalenhoef AF Defects of lipoprotein metabolism in familial combined hyperlipidaemia Curr Opin Lipidol 1998 9 189 96
3. De Graaf J Veerkamp MJ Stalenhoef AFH Metabolic pathogenesis of familial combined hyperlipidaemia with emphasis on insulin resistance, adipose tissue metabolism and free fatty acids J R Soc Med 2002 95 Suppl. 42 46 53
4. Pajukanta P Lilja HE Sinsheimer JS et al. Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1) Nat Genet 2004 36 371 6
5. Bredie SJ Tack CJ Smits P Stalenhoef AF Nonobese patients with familial combined hyperlipidemia are insulin resistant compared with their nonaffected relatives Arterioscler Thromb Vasc Biol 1997 17 1465 71
6. Davidson MB Clinical implications of insulin resistance syndromes Am J Med 1995 99 420 6
7. DeFronzo RA Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes Diabetes Rev 1997 5 177 269
8. Day C Thiazolidinediones: a new class of antidiabetic drugs Diabet Med 1999 16 179 92
9. Yki-Jarvinen H Thiazolidinediones N Engl J Med 2004 351 1106 18
10. Mori Y Murakawa Y Okada K et al. Effect of troglitazone on body fat distribution in type 2 diabetic patients Diabetes Care 1999 22 908 12
11. Bays H Mandarino L DeFronzo RA Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach J Clin Endocrinol Metab 2004 89 463 78
12. Füllert S Schneider F Haak E et al. Effects of pioglitazone in non-diabetic patients with arterial hypertension: a double-blind, placebo-controlled study J Clin Endocrinol Metab 2002 87 5503 6
13. Parulkar AA Pendergrass ML Granda-Ayala R Lee TR Fonseca VA Nonhypoglycemic effects of thiazolidinediones Ann Intern Med 2001 134 61 71
14. van Wijk JPH de Koning EJP Martens EP Rabelink TJ Thiazolidinediones and blood lipids in type 2 diabetes Arterioscler Thromb Vasc Biol 2003 23 1744 9
15. Khan MA St Peter JV Xue JL A prospective, randomized comparison of the metabolic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone Diabetes Care 2002 25 708 11
16. Derosa G Cicero AF Gaddi A et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial Clin Ther 2004 26 744 54
17. Chiquette E Ramirez G Defronzo R A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors Arch Intern Med 2004 164 2097 104
18. Lawrence JL Reid J Taylor GJ Stirling C Reckless JPD Favourable effects of pioglitazone and metfomin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes Diabetes Care 2004 27 41 6
19. Winkler K Konrad T Füllert S et al. Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension Diabetes Care 2003 26 2588 94
20. Diep QN El Mabrouk M Cohn JS et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma Circulation 2002 105 2296 302
21. Kotchen TA Reddy S Zhang HY Increasing insulin sensitivity lowers blood pressure in the fructose-fed rat Am J Hypertens 1997 10 1020 6
22. Kotchen TA Zhang HY Reddy S Hoffmann RG Effect of pioglitazone on vascular reactivity in vivo and in vitro Am J Physiol 1996 270 R660 6
23. Pistrosch F Passauer J Fischer S Fuecker K Hanefeld M Gross P In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control Diabetes Care 2004 27 484 90
24. Kelley DE Goodpaster BH Skeletal muscle triglyceride: an aspect of regional adiposity and insulin resistance Diabetes Care 2001 24 933 41
25. Boesch C Kreis R Observation of intramyocellular lipids by 1H-magnetic resonance spectroscopy Ann N Y Acad Sci 2000 904 25 31
26. Veerkamp MJ de Graaf J Hendriks JC Demacker PN Stalenhoef AF Nomogram to diagnose familial combined hyperlipidemia on the basis of results of a 5-year follow-up study Circulation 2004 109 2980 5
27. Abumrad NN Rabin D Diamond MP Lacy WW Use of a heated superficial hand vein as an alternative site for the measurement of amino acid concentrations and for the study of glucose and alanine kinetics in man Metabolism 1981 30 936 40
28. Ryysy L Hakkinen AM Goto T et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients Diabetes 2000 49 749 58
29. Seppala-Lindroos A Vehkavaara S Hakkinen AM et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men J Clin Endocrinol Metab 2002 87 3023 8
30. Frahm J Bruhn H Gyngell ML Merboldt KD Hänicke W Sauter R Localized high-resolution proton NMR spectroscopy using stimulated echoes: initial applications to human brain in vivo Magn Reson Med 1989 9 79 93
31. 1H NMR study Am J Physiol Endocrinol Metab 2002 282 E95 106
32. Demacker PN Hijmans AG Vos-Janssen HE van't Laar A Jansen AP A study of the use of polyethylene glycol in estimating cholesterol in high-density lipoprotein Clin Chem 1980 26 1775 9
33. Friedewald WT Levy RI Fredrickson DS Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 1972 18 499 502
34. Swinkels DW Hak-Lemmers HL Demacker PN Single spin density gradient ultracentrifugation method for the detection and isolation of light and heavy low density lipoprotein subfractions J Lipid Res 1987 28 1233 9
35. de Graaf J Swinkels DW de Haan AF Demacker PN Stalenhoef AF Both inherited susceptibility and environmental exposure determine the low-density lipoprotein-subfraction pattern distribution in healthy Dutch families Am J Hum Genet 1992 51 1295 310
36. Stalenhoef AF de Graaf J Wittekoek ME Bredie SJ Demacker PN Kastelein JJ The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia Atherosclerosis 2000 153 129 38
37. Demacker PN Veerkamp MJ Bredie SJ Marcovina SM de Graaf J Stalenhoef AF Comparison of the measurement of lipids and lipoproteins versus assay of apolipoprotein B for estimation of coronary heart disease risk: a study in familial combined hyperlipidemia Atherosclerosis 2000 153 483 90
38. Lopes-Virella MF Virella G Evans G Malenkos SB Colwell JA Immunonephelometric assay of human apolipoprotein AI Clin Chem 1980 26 1205 8
39. Abbink EJ Walker AJ van der Sluijs HA Tack CJ Smits P No role of calcium- and ATP-dependent potassium channels in insulin-induced vasodilation in humans in vivo Diab Metab Res Rev 2002 18 143 8
40. DeFronzo RA Tobin JD Andres R Glucose clamp technique: a method for quantifying insulin secretion and resistance Am J Physiol 1979 237 E214 23
41. Matthews DR Hosker JP Rudenski AS Naylor BA Treacher DF Turner RC Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 1995 28 412 9
42. Kipnes MS Krosnick A Rendell MS Egan JW Mathisen AL Schneider RL Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study Am J Med 2001 111 10 7
43. Miyazaki Y Mahankali A Matsuda M et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients J Clin Endocrinol Metab 2002 87 2784 91
44. Mayerson AB Hundal RS Dufour S et al. The effects of rosiglitazone on insulin sensitivity, lipolysis and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes Diabetes 2002 51 797 802
45. Bajaj M Suraamornkul S Piper P et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients J Clin Endocrinol Metab 2004 89 200 6
46. Petersen KF Dufour S Befroy D Lehrke M Hendler RE Shulman GI Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes Diabetes 2005 54 603 8
47. Wang TD Chen WJ Lin JW Cheng CC Chen MF Lee YT Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles Atherosclerosis 2003 170 315 23